Evidence map›Paper›PMID 30063647›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2018

Brief Report: Identification of Elite and Viremic Controllers From a Large Urban HIV Ambulatory Center in Kampala, Uganda.

Alex Kayongo, Elena Gonzalo-Gil, Emrah Gümüşgöz, Anxious J Niwaha, Fred Semitala, Robert Kalyesubula, Bernard S Bagaya, Moses L Joloba, Richard E Sutton

Open access · hybridAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. BeyondFrontiers in genetics · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Alex KayongoDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.
Elena Gonzalo-GilSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Emrah GümüşgözSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Anxious J NiwahaMakerere University Joint AIDS Program, Kampala, Uganda.
Fred SemitalaMakerere University Joint AIDS Program, Kampala, Uganda.
Robert KalyesubulaDepartment of Internal Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Bernard S BagayaDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.
Moses L JolobaDepartment of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.
Richard E SuttonSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Makerere University · UGYale University · US

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Host Genetic Control of HIVDP1DA036463 · NIDA · YALE UNIVERSITY · PI SUTTON, RICHARD · 2013 to 2017
$3.7M
NIAID NIH HHS P30 AI050410NIDA NIH HHS DP1 DA036463Wellcome Trust 107743DUNNE
6 · The paper itself

Abstract

backgroundThroughout the world, there are antiretroviral therapy-naive HIV+ individuals who maintain elevated peripheral CD4 T-cell counts, historically referred to as long-term nonprogressors (LTNPs). With recent improvements in viral load (VL) detection methods to levels as low as 20 copies per milliliter, 2 subsets of LTNPs have been defined: elite controllers (ECs), with undetectable VLs for at least 6-12 months, and viremic controllers (VCs), with VLs between 200 and 2000 copies per milliliter. ECs and VCs have been extensively studied in the developed world to determine underlying mechanisms responsible for virologic control. In sub-Saharan Africa, most studies have characterized LTNPs based on immunologic criteria making it difficult to compare findings with the Western cohorts, which use virologic criteria. Here, we describe a cohort of Uganda ECs and VCs attending a large HIV ambulatory center in Kampala, Uganda, based initially on CD4 counts and confirmed by repeated VL measurements.

methodsA cross-sectional study was conducted among 14,492 HIV-infected, antiretroviral therapy-naive individuals aged 18 years and older under care for at least 5 years with serial peripheral CD4 counts ≥500 cells/μL. Among those, we determined the frequency of individuals with VLs <2000 copies per milliliter for at least 6 months.

resultsWe report a prevalence of 0.26% (38/14,492) of HIV controllers in the clinic. We identified 36 ECs and 2 VCs. These individuals were middle-aged with an average CD4 count of 858 ± 172 (mean ± SD, 95% confidence interval: 795 to 921). Their average duration in HIV care was 7.4 ± 2.1 years (mean ± SD, 95% confidence interval: 6.6 to 8.1). The majority of EC/VCs were women (87%, 33/38), reflecting the demographics of the urban clinic.

conclusionsFor the first time, this study demonstrates the frequency of EC/VCs in a large urban clinic in Uganda. Further study of these East African subjects may provide insights into how some individuals are able to control HIV in the absence of medications.

Indexed as

HIV Long-Term SurvivorsViral LoadAdultCD4 Lymphocyte CountCross-Sectional StudiesFemaleHIV InfectionsHumansMaleMiddle AgedPrevalenceUganda

Identifiers

PMID30063647
PMCPMC6186412
OpenAlexW2885703299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.